BioSig to Host Live Roundtable Webinar to Discuss Clinical Data Delivered With Its Signal Processing Technology For Arrhythmia Care
BioSig Technologies (Nasdaq: BSGM) will host a live roundtable webinar on November 18, 2021, discussing results from the PURE EP 2.0 study recently published in the Journal of Cardiovascular Electrophysiology. The event, titled “PURE EP 2.0 Study Results: From Clinical Data to Clinical Applications,” will feature experts Andrea Natale, Amin Al-Ahmad, and Wendy Tzou, who will review the impact of high-fidelity signals on cardiac ablation procedures. The study reported a 75% improvement in intracardiac signal quality and a 93% consensus among blinded reviewers.
- 75% overall improvement in intracardiac signal quality.
- 93% consensus across blinded reviewers regarding signal fidelity.
- Expert-led roundtable discussion highlighting clinical applications.
- None.
Discussion led by three industry experts scheduled for November 18, 2021 at 8pm ET
Westport, CT, Nov. 11, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced
that it will host a live roundtable webinar to discuss the PURE EP 2.0 study results recently published in the Journal of Cardiovascular Electrophysiology. The live webinar, titled, “PURE EP 2.0 Study Results: From Clinical Data to Clinical Applications,” will air on Thursday, November 18, 2021, from 8pm -9pm EST.
The roundtable will be led by three industry experts: Andrea Natale, M.D., Executive Medical Director, and Amin Al-Ahmad, M.D., Cardiac Electrophysiologist at St. David’s Medical Center in Austin TX; and Wendy Tzou, MD., Director of Electrophysiology at the University of Colorado in Denver. The faculty panel will review the recently published study results and discuss the integration of high-fidelity signals into the current procedural workflow and the impact of advanced signal processing technology on cardiac ablation procedures and beyond.
To register for the event, please click here.
Webinar Details:
Date: Thursday, November 18, 2021
Time: 8 pm – 9 pm (ET)
Clinical data acquired by the PURE EP™ System in a multi-center study at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic Jacksonville and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library. Study results showed
About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).
The Company’s first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
FAQ
What is the PURE EP 2.0 study about?
When will the BioSig Technologies webinar take place?
Who will lead the BioSig Technologies roundtable discussion?
What were the results of the PURE EP study?
How can I register for the BioSig Technologies webinar?
